Findings

What do systematic reviews say?

216 questions · 226 findings · 24 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 84 · 37.2%GRADE not reported 5 · 2.2%Very low 73 · 32.3%Low 39 · 17.3%Moderate 25 · 11.1%High 0 · 0%

Diet vs physical activity or standard treatment

Development of type 2 diabetes · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 530 participants
Very low

Intervention not reported

All‐cause mortality · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 179 participants
Very low

Intervention not reported

Serious adverse events · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2312 participants
Low

Intervention not reported

Cardiovascular mortality · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2281 participants
Very low

Intervention not reported

(1) Non‐fatal myocardial infarction (2) Non‐fatal stroke (3) Congestive heart failure · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 2279 participants
Very low

Intervention not reported

Health‐related quality of life SF‐36 scale: total score 0‐100, 8 subscales. Higher values mean better health‐related quality of life. · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1791 participants
Very low

Intervention not reported

Socioeconomic effects · people at risk for development of T2DM

The review found no eligible studies for this question.

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Incidence of T2DM Definition: WHO criteria · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 179 participants
Very low

Intervention not reported

Serious adverse events · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 179 participants
Very low

Intervention not reported

Cardiovascular mortality · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 179 participants
Very low

Intervention not reported

(1) Non‐fatal myocardial infarction (2) Non‐fatal stroke (3) Congestive heart failure · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 2 participants
Very low

Intervention not reported

Health‐related quality of life · people at risk for development of T2DM

The review found no eligible studies for this question.

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Socioeconomic effects · people at risk for development of T2DM

The review found no eligible studies for this question.

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2281 participants
Very low

Intervention not reported

Incidence of T2DM Definition/description: 1 trial established the diagnosis of T2DM defined as HbA1c ≥ 6.5%, or fasting plasma glucose ≥ 7.0 mmol/L, or 2‐hour plasma glucose post‐challenge (oral glucose tolerance test) ≥ 11.1 mmol/L (SCALE). Other... · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2243 participants
Very low

Intervention not reported

All‐cause mortality · people at risk for the development of type 2 diabetes mellitus

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 274 participants
Very low

Intervention not reported

Serious adverse events · people at risk for the development of type 2 diabetes mellitus

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9306 participants
Moderate

Intervention not reported

Cardiovascular mortality · people at risk for the development of type 2 diabetes mellitus

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9306 participants
Moderate

Intervention not reported

(a) Non‐fatal myocardial infarction (b) Non‐fatal stroke (c) Congestive heart failure · people at risk for the development of type 2 diabetes mellitus

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9306 participants
Moderate

Intervention not reported

Health‐related quality of life · people at risk for the development of type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found